Table 4.
Pharmacy utilization for subjects with and without atrial fibrillation after coronary artery bypass graft surgery
| No fibrillation (n = 482) |
Fibrillation (n= 238) |
||||
|---|---|---|---|---|---|
| Drug | No. (%) of subjects receiving drug |
No. of drug days per subject mean (SD) |
No. (%) of subjects receiving drug |
No. of drug days per subject mean (SD) |
P* |
| Oral and intravenous cardiac drugs† |
|||||
| β-Blockers | 446 (92.5) | 4.2 (1.4) | 221 (92.9) | 5.1 (2.5) | <.001 |
| Calcium channel blockers |
156 (32.4) | 2.2 (1.8) | 137 (57.6) | 2.7 (2.2) | .04 |
| Angiotensin- converting enzyme inhibitors |
138 (28.6) | 3.6 (2.0) | 79 (33.2) | 4.7 (2.8) | .002 |
| Digoxin | 52 (10.8) | 3.1 (1.9) | 142 (59.7) | 3.8 (2.4) | .09 |
| Adenosine | 0 (0) | 0 (0) | 6 (2.5) | 1 (1) | ND |
| Procainamide | 4 (0.8) | 1.8 (0.5) | 186 (78.2) | 3.8 (2.6) | .12 |
| Lidocaine infusion | 10 (2.1) | 1 (0) | 7 (2.9) | 1 (0) | ND |
| Quinidine | 0 (0) | 0 (0) | 0 (0) | 0 | ND |
| Amiodarone | 2 (0.4) | 3 (2.8) | 4 (1.7) | 3.3 (0.9) | ND |
| Anticoagulants | |||||
| Heparin | 461 (95.6) | 1.2 (0.9) | 234 (98.3) | 2.1 (2.1) | <.001 |
| Warfarin | 64 (13.3) | 2.8 (1.5) | 49 (20.6) | 3.1 (2.0) | .49 |
| Diuretics | |||||
| Furosemide | 477 (99.0) | 4.0 (1.4) | 236 (99.2) | 5.3 (2.1) | <.001 |
| Bumetanide | 9 (1.9) | 2.0 (2.0) | 3 (1.3) | 2.0 (1) | ND |
| Electrolytes | |||||
| Potassium | 481 (99.8) | 4.2 (1.3) | 237 (99.6) | 5.3 (2.0) | <.001 |
| Calcium | 317 (65.8) | 1.0 (0.1) | 164 (68.9) | 1.1 (0.3) | .42 |
| Magnesium | 481 (99.8) | 1.7 (0.9) | 238 (100) | 2.7 (1.1) | <.001 |
ND indicates that statistical analysis was not done because of the small number of subjects who received this medication.
*
P values are based on comparison of data for no. of drug days per subject.
†
Bonferroni correction for 5 variables significant at P= .01.